Navigation Links
Hooper Holmes Appoints Leslie Hudson, PhD, to Board of Directors
Date:11/5/2007

BASKING RIDGE, N.J., Nov. 5 /PRNewswire-FirstCall/ -- Hooper Holmes, Inc. (AMEX: HH) today announced that Leslie Hudson, PhD, Interim President and CEO of Nabi Biopharmaceuticals Inc. (Nasdaq: NABI), has been reappointed to the Company's Board of Directors. Dr. Hudson was previously a member of the Board from 2005 to 2006. He replaces Paul Kolacki who retired as a Director in September 2007.

"We know and respect Les, and we are pleased to welcome him back to our Board," said Benjamin A. Currier, Chairman of the Board of Hooper Holmes. "His experience in the pharmaceutical, healthcare and health information industries, as well as his strategic and operational business insights, will be key assets as we look to the future."

"Hooper Holmes is in the process of a major turnaround, making this a very exciting time to return to the Board," said Dr. Hudson. "While in a sense I am picking up where I left off, the Company has changed significantly over the past year, expanding into new areas and revitalizing its core business. I look forward to offering my support as the Company moves into the next phase of its development."

Dr. Hudson was appointed Interim President and Chief Executive Officer of Nabi Biopharmaceuticals in February 2007 and has been a director of the Company since August 2005. Prior to joining Nabi, he served as Chief Executive Officer and President of DOV Pharmaceutical, Inc., from June 2005 to July 2006.

Dr. Hudson served as Vice Provost for Strategic Initiatives at the University of Pennsylvania from 2003 to June 2005. From 1995 to 2003 he served in several positions at Pharmacia Corp., including senior vice president of research and exploratory development, senior vice president of emerging technology and commercial development and general manager and group vice president of ophthalmology.

Prior to his tenure at Pharmacia, Dr Hudson worked at Repligen Corporation, based in Cambridge, Massachusetts. He also served in several senior research positions at GlaxoWellcome (GlaxoSmithKline plc) from 1988 to 1994 including head of cancer, metabolic and hyperproliferative disease and vice president for discovery research, which included responsibility for the company's genomics program.

About Hooper Holmes

Hooper Holmes is the leader in collecting personal health data and transforming it into useful information, enabling customers to take actions that manage or reduce their risks and expenses. As the leading provider of risk assessment services for the insurance industry, Hooper Holmes provides insurers with the widest range of medical exam, data collection, laboratory testing and underwriting services in the industry.

With presence in over 250 markets and a network of more than 9,000 examiners, Hooper Holmes can arrange a medical exam anywhere in the U.S. and deliver the results to its customers. Each year we arrange more than 2.3 million medical exams and process 3.8 million specimens in our laboratory. We provide a complete service for wellness, disease management, and managed care companies including scheduling support, fulfillment of supplies, blood collection kits, medical screenings, lab testing and data transmission. We underwrite 300,000 cases annually and complete more than two million telephone interviews. We are also a leading provider of medical claims evaluation services used by property and casualty insurance carriers, law firms, self- insureds and third-party administrators to handle personal injury and accident claims.

Certain information contained herein includes information that is forward- looking. The matters referred to in forward-looking statements may be affected by the risks and uncertainties involving the Company's business. These forward-looking statements are qualified in their entirety by cautionary statements contained in the Company's Securities and Exchange Commission filings. The Company disclaims any obligation to update these forward-looking statements.


'/>"/>
SOURCE Hooper Holmes, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Hooper Holmes Names Chris Behling President of Health & Wellness Division
2. Hooper Holmes Launches Health & Wellness Division at 2007 Disease Management Leadership Forum and Integrated Care Summit
3. Hooper Holmes Concludes Sale of Medicals Direct
4. Hooper Holmes to Exhibit at the 2007 Sixth Annual Association of Home Office Underwriters Conference
5. Hooper Holmes Introduces Mature Assessment
6. Hooper Holmes Announces Third Quarter Earnings Release Date and Conference Call Information
7. WorldHeart Appoints David Pellone Chief Financial Officer
8. Novo Nordisk Appoints New Leader of North American Business
9. Millstone Medical Outsourcing Appoints Operations Manager of New Memphis, TN, Facility
10. China Holdings Appoints Ronald Shon Chairman of Advisory Board to Its Wholly-Owned Subsidiary China Power, Inc.
11. Resonant Medical Appoints New Vice President of Global Sales
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... (PRWEB) , ... June 27, ... ... in the patient payment industry today announced its strategic partnership with Connance, ... system workflows. , The two companies’ proven, proprietary technology combine to provide ...
(Date:6/26/2016)... California (PRWEB) , ... June 26, 2016 , ... Pixel ... Cut Pro X. , "Film editors can give their videos a whole new perspective ... Christina Austin - CEO of Pixel Film Studios. , ProSlice Levels contains over ...
(Date:6/25/2016)... ... , ... Austin residents seeking Mohs surgery services, can now turn to Dr. ... Russell Peckham for medical and surgical dermatology. , Dr. Dorsey brings specialization to include ... in Mohs Micrographic Surgery completed by Dr. Dorsey was under the direction of Glenn ...
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. Calvin Johnson has ... he has implemented orthobiologic procedures as a method for treating his patients. The ... first doctors to perform the treatment. Orthobiologics are substances that orthopaedic surgeons use ...
(Date:6/24/2016)... ... June 24, 2016 , ... June 19, 2016 is ... associated with chronic pain and the benefits of holistic treatments, Serenity Recovery Center ... suffering with Sickle Cell Disease. , Sickle Cell Disease (SCD) is a disorder of ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... Roche (SIX: RO, ROG; OTCQX: RHHBY) announced ... BRAHMS PCT (procalcitonin) assay as a dedicated testing solution ... this clearance, Roche is the first IVD company in ... sepsis risk assessment and management. PCT is ... levels in blood can aid clinicians in assessing the ...
(Date:6/23/2016)... 2016 Capricor Therapeutics, Inc. ... biotechnology company focused on the discovery, development and ... enrollment in its ongoing randomized HOPE-Duchenne clinical trial ... of its 24-patient target. Capricor expects the trial ... of 2016, and to report top line data ...
(Date:6/23/2016)... -- Bracket , a leading clinical trial technology and ... platform, Bracket eCOA (SM) 6.0, at the 52 nd ... 2016 in Philadelphia , Pennsylvania.  A demonstration ... of its kind to fully integrate with RTSM, will be ... is a flexible platform for electronic clinical outcomes assessments that ...
Breaking Medicine Technology: